ArticleParasites & vectors2026
Efficacy of sarolaner in Simparica
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHaemaphysalis longicornis (Asian longhorned tick) is an invasive species now established in the Northeastern and Mid-Atlantic USA. It feeds on mammalian wildlife, livestock, birds, cats, dogs, and humans. Simparica
methodsTwo laboratory studies were conducted using 30 dogs each, randomized into three groups (n = 10/group): placebo (Pet Tabs
resultsAdequate challenge was demonstrated in both studies on the basis of live tick counts at each time point. For all sarolaner-treated groups, mean live counts were significantly (P ≤ 0.0005) lower than those for the placebo at all time points. For Simparica, in Study 1, the percentage reductions were 100% for all time points up to Day 39. On Days 51 and 65, the percentage reductions were 98.9% and 82.4%, respectively. In Study 2, reductions were 99.7-100% up to Day 65. For Simparica Trio, in Study 1, percentage reductions were 100% up to Day 51. On Day 65, the percentage reduction was 78.4%. In Study 2, reductions were 99.6-100% up to Day 39 and 97.6% and 94.1% on Days 51 and 65, respectively.
conclusionsResults from these controlled studies demonstrated high efficacy (78.4-100%) of Simparica and Simparica Trio in reducing existing and subsequent infestations of H. longicornis within 48 h for up to 65 days post treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.